WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006086561) NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/086561    International Application No.:    PCT/US2006/004599
Publication Date: 17.08.2006 International Filing Date: 08.02.2006
IPC:
A61K 39/00 (2006.01), A61K 39/395 (2006.01), A61K 39/42 (2006.01), A61K 39/215 (2006.01)
Applicants: NEW YORK BLOOD CENTER [US/US]; 310 East 67th Street, New York, NY 10021 (US) (For All Designated States Except US).
JIANG, Shibo [US/US]; (US) (For US Only).
HE, Yuxian [CN/US]; (US) (For US Only)
Inventors: JIANG, Shibo; (US).
HE, Yuxian; (US)
Agent: CHAN, Albert, Wai-Kit; World Plaza, Suite 604, 141-07 20th Avenue, Whitestone, NY 11357 (US)
Priority Data:
60/651,046 08.02.2005 US
11/141,925 31.05.2005 US
60/576,118 02.06.2004 US (IA Considered Withdrawn 20.06.2006)
Title (EN) NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS
(FR) NEUTRALISATION D'ANTICORPS MONOCLONAUX CONTRE LE CORONAVIRUS ASSOCIE AU SYNDROME RESPIRATOIRE AIGU SEVERE
Abstract: front page image
(EN)The present invention provides an isolated antibody capable of binding to the receptor- binding domain of the spike protein of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) so as to competitively inhibit the binding of the SARS-CoV to host cells. These mAbs or substances can be used: 1) as passive-immunizing agents for prevention of SARS-CoV infection; 2) as biological reagents for diagnosis of SARS-CoV infection; 3) as immunotherapeutics for early treatment of SARS-CoV infection; and 4) as probes for studying the immunogenicity, antigenicity, structure, and function of the SARS- CoV S protein.
(FR)L'invention concerne un anticorps isolé capable de se lier au domaine de liaison au récepteur de la protéine spicule du coronavirus associé au syndrome respiratoire aigu sévère (SARS-CoV) afin d'inhiber, de manière compétitive, la liaison du SARS-CoV avec des cellules hôtes. On peut utiliser ces mAbs ou substances: 1) comme agents d'immunisation passive pour prévenir une infection par le SARS-CoV; 2) comme réactifs biologiques pour diagnostiquer une infection par le SARS-CoV; 3) comme thérapies immunitaires pour traiter précocement une infection par le SARS-CoV; et 4) comme sondes pour étudier l'immunogénicité, l'antigénicité, la structure et la fonction de la protéine SARS- CoV S.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)